WordNet

a substance that exerts some force or effect
a businessman who buys or sells for another in exchange for a commission (同)factor, broker
any agent or representative of a federal agency or bureau (同)federal agent
a representative who acts on behalf of other persons or organizations
an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
how long something has existed; "it was replaced because of its age"
a time of life (usually defined in years) at which some particular qualification or power arises; "she was now of school age"; "tall for his eld" (同)eld
begin to seem older; get older; "The death of his wife caused him to age fast"
make older; "The death of his child aged him tremendously"
a drug that causes dilation of blood vessels (同)vasodilative

PrepTutorEJDIC

『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
〈U〉(一般に)『年齢』,寿命;〈C〉(個々の)『年齢』,年 / 〈U〉成年(おとなとしての資格・権利を得る年齢;通例18または21歳) / 〈U〉『老齢』;《集合的に》老人たち / 〈U〉(人生の)『一時期』;〈C〉世代(generation) / 〈U〉〈C〉《しばしばA-》(歴史上の)『時代』 / 〈C〉《話》長い間 / 年をとる,ふける;〈物が〉古くなる / 〈年〉'を'とらせる;〈物〉'を'古びさせる

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 負荷時の放射性核種心筋血流イメージングの概要 overview of stress radionuclide myocardial perfusion imaging
2. 慢性僧帽弁閉鎖不全症の血管拡張療法 vasodilator therapy in chronic mitral regurgitation
3. 負荷心エコーの概要 overview of stress echocardiography
4. 成人における肺高血圧症の治療 treatment of pulmonary hypertension in adults
5. 成人への一酸化窒素吸入療法：生物学と適用対象 inhaled nitric oxide in adults biology and indications for use

English Journal

Hydrogen sulphide-mediated vasodilatation involves the release of neurotransmitters from sensory nerves in pressurized mesenteric small arteries isolated from rats.

White BJ, Smith PA, Dunn WR.SourceCardiovascular Research Group, School of Biomedical Sciences, University of Nottingham, Nottingham, NG7 2UH, United Kingdom.
British journal of pharmacology.Br J Pharmacol.2012 Aug 28. doi: 10.1111/j.1476-5381.2012.02187.x. [Epub ahead of print]
BACKGROUND & PURPOSE: Hydrogen sulphide (H(2) S) is a gas that has recently been shown to have biological activity. In the majority of blood vessels studied so far, H(2) S has been shown to cause vasorelaxation, although contractile responses have been reported. In the present study we have made
PMID 22928888

A new epoprostenol formulation for the treatment of pulmonary arterial hypertension.

Fuentes A, Coralic A, Dawson KL.AbstractPurpose The pharmacology and pharmacokinetics of a novel formulation of epoprostenol for the treatment of pulmonary arterial hypertension (PAH) are reviewed, with guidance on addressing a number of important safety considerations. Summary Epoprostenol is a direct vasodilator of the pulmonary and systemic vasculature indicated for improving exercise capacity in patients with PAH. Veletri, a recently approved formulation of epoprostenol for continuous i.v. infusion, offers increased stability relative to other available epoprostenol products. Therefore, the use of Veletri can lessen the therapy burden associated with the other available formulation of the drug by allowing for the advance preparation of infusion pump cassettes (at certain concentrations) and administration at room temperature without the need for cooling with ice packs. Sterility, however, is of concern with outpatient preparation of epoprostenol-containing cassettes stored for the maximum duration according to stability guidelines. All epoprostenol infusions are classified as high-risk therapies due to complex dosing, the drug's short half-life, and the potential for life-threatening rebound PAH with abrupt discontinuation. Adverse effects reported in ≥10% of participants in clinical trials of Veletri included flushing (58%), headache (49%), nausea or vomiting (32%), hypotension (16%), chest pain (11%), and anxiety, nervousness, or agitation (11%). As with other epoprostenol formulations, the use of Veletri requires an evaluation of health-system medication-use practices to ensure patient safety. Conclusion Veletri provides an epoprostenol therapy option that reduces some of the inconveniences of the other formulation. Drug stability is dependent on cassette concentrations, which may be limited by sterility concerns with outpatient preparation. Use of this new agent within the health system requires an evaluation of practices to ensure patient safety.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.Am J Health Syst Pharm.2012 Aug 15;69(16):1389-93.
Purpose The pharmacology and pharmacokinetics of a novel formulation of epoprostenol for the treatment of pulmonary arterial hypertension (PAH) are reviewed, with guidance on addressing a number of important safety considerations. Summary Epoprostenol is a direct vasodilator of the pulmonary and sy
PMID 22855104